Page last updated: 2024-11-05

dimethyl sulfone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID6213
CHEMBL ID25028
CHEBI ID9349
MeSH IDM0085668

Synonyms (75)

Synonym
methylsulfone
CHEBI:9349 ,
dimethyl sulphone
sulfonyldimethane
sulphonylbismethane
ccris 2938
einecs 200-665-9
nsc 63345
ai3-25306
methylsulfonyl methane
nsc63345
methylsulfonylmethane
nsc-63345
methyl sulfone
methane, sulfonylbis-
inchi=1/c2h6o2s/c1-5(2,3)4/h1-2h
dimethyl sulfone ,
sulfonylbismethane
67-71-0
dimethyl sulfone, 98%
NCGC00095990-01
MOLMAP_000019
SPECTRUM1505358
dimethylsulfone
methanesulfonylmethane
CHEMBL25028 ,
M0509
M1239
bdbm50026473
A835859
EN300-79559
(methylsulfonyl)methane
unii-9h4po4z4ft
methane, 1,1'-sulfonylbis-
9h4po4z4ft ,
FT-0625160
AKOS015897615
dmso2
mythylsulfonylmethane (msm) [vandf]
methylsulfonylmethane [vandf]
dimethyl sulfone [inci]
methyl sulphone
dimethyl sulfoxide impurity a [ep impurity]
dimethyl sulfone [mi]
methylsulfonylmethane [who-dd]
dimethyl sulfone [mart.]
methylsulfonylmethane [usp-rs]
methosulfonylmethane
CCG-214558
(methylsulphonyl)methane
dimethylsulphone
methy sulfone
dimethylsulfon
methyl sulfonyl methane
sulfone, dimethyl-
dtxcid2023937
cas-67-71-0
NCGC00357027-01
tox21_303712
dtxsid4043937 ,
Z417007936
mfcd00007566
methylsulfonylmethane, united states pharmacopeia (usp) reference standard
dimethyl sulfone, standard for quantitative nmr, tracecert(r)
sulfonylbis-methane
opti msm
lignisul msm
methylsulfonylmethane, pharmaceutical secondary standard; certified reference material
F0001-1776
Q423842
DB14090
AMY25756
D70240
CS-0017786
HY-Y1314

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" This study also examined possible adverse reactions associated with methylsulfonylmethane supplementation."( A multicentered, open-label trial on the safety and efficacy of methylsulfonylmethane in the treatment of seasonal allergic rhinitis.
Barrager, E; Schauss, AG; Schiller, RN; Veltmann, JR, 2002
)
0.31
" MSM administered in a single gavage dose of 2 g/kg resulted in no adverse events or mortality."( Toxicity of methylsulfonylmethane in rats.
Financsek, I; Glávits, R; Horváth, K; Noker, PE; Schauss, AG; Somfai-Relle, S, 2002
)
0.31
" As a Generally Recognized As Safe (GRAS) approved substance, MSM is well-tolerated by most individuals at dosages of up to four grams daily, with few known and mild side effects."( Methylsulfonylmethane: Applications and Safety of a Novel Dietary Supplement.
Benjamin, RL; Bloomer, RJ; Butawan, M, 2017
)
0.46
" In conclusion, oral MSM at either acute (single dose at 1,000 to 2,000 mg/kg BW) or sub-chronic (1,500 mg/kg BW daily for 21 D) concentrations did not cause any adverse effects on growth or clinical outcomes and appeared to be absorbed and distributed throughout the body."( Toxicity and tissue distribution of methylsulfonylmethane following oral gavage in broilers.
Abdul Rasheed, MS; Bauer, LL; Dilger, RN; Oelschlager, ML; Smith, BN; Whelan, RA, 2019
)
0.51
"To ensure that 16 weeks of methylsulfonylmethane (MSM) does not cause adverse effects in patients with the musculoskeletal disorders of osteoarthritis and back pain."( Methylsulfonylmethane for treatment of low back pain: A safety analysis of a randomized, controlled trial.
Crawford, A; Crawford, P; Lystrup, R; Nielson, F, 2019
)
0.51
" Adverse events were monitored weekly."( Efficacy and safety of a supplement combination on hand pain among people with symptomatic hand osteoarthritis an internet-based, randomised clinical trial the RADIANT study.
Deveza, LA; Eyles, J; Fedorova, T; Hunter, DJ; Liu, X; McLachlan, AJ; Robbins, S; Virk, S, 2021
)
0.62

Pharmacokinetics

ExcerptReferenceRelevance
" The objective of this study was to evaluate the pharmacokinetic profile and distribution of radiolabeled MSM in rats."( Pharmacokinetics and distribution of [35S]methylsulfonylmethane following oral administration to rats.
Ames, GB; Appleton, J; Magnuson, BA, 2007
)
0.34
" It is important to understand whether any pharmacokinetic interactions are among the major constituents of these supplements so as to provide information when considering the combination use of these supplements."( Pharmacokinetic assessment of constituents of Boswellia serrata, pine bark extracts, curcumin in combination including methylsulfonylmethane in healthy volunteers.
Adiwidjaja, J; Eagles, SK; Eyles, J; Hunter, DJ; Liu, X; McLachlan, AJ; Wang, X, 2020
)
0.56
"The pharmacokinetics of each constituent was characterized, and there were no significant differences in the pharmacokinetic profiles of the constituents when administered as a combination, relative to the constituents when administered alone (P > 0."( Pharmacokinetic assessment of constituents of Boswellia serrata, pine bark extracts, curcumin in combination including methylsulfonylmethane in healthy volunteers.
Adiwidjaja, J; Eagles, SK; Eyles, J; Hunter, DJ; Liu, X; McLachlan, AJ; Wang, X, 2020
)
0.56
"These data suggest that interactions between the major constituents of this supplement combination are unlikely and therefore could be investigated to manage patients with osteoarthritis without significant concerns for possible pharmacokinetic interactions."( Pharmacokinetic assessment of constituents of Boswellia serrata, pine bark extracts, curcumin in combination including methylsulfonylmethane in healthy volunteers.
Adiwidjaja, J; Eagles, SK; Eyles, J; Hunter, DJ; Liu, X; McLachlan, AJ; Wang, X, 2020
)
0.56

Compound-Compound Interactions

ExcerptReferenceRelevance
" Therefore, we tested metal chelation by means of ethylenediaminetetraacetic acid (EDTA) combined with the permeability enhancer methylsulfonylmethane (MSM) applied topically on the eye to determine if this noninvasive treatment is neuroprotective in rat optic nerve and retinal ganglion cells exposed to oxidative stress induced by elevated IOP."( Metal chelator combined with permeability enhancer ameliorates oxidative stress-associated neurodegeneration in rat eyes with elevated intraocular pressure.
Ansari, NH; Campbell, GA; Hogan, D; Liu, P; Shoeb, M; Syed, MF; Tang, L; Wang, CZ; Zhang, M, 2014
)
0.4

Bioavailability

ExcerptReferenceRelevance
"To maximize the biological activity of branched-chain amino acids (BCAAs), it is necessary to find a new excipient agent to increase the bioavailability of BCAAs in protein mixtures."( Impact of soy lecithin, zinc oxide, and methylsulfonylmethane, as excipient ingredients, on the bioaccessibility and intestinal transport of branched-chain amino acids from animal and plant protein mixtures.
Lee, CY; Lee, DY; Oh, JH; Shim, SM; Shin, JN, 2021
)
0.62

Dosage Studied

ExcerptRelevanceReference
" In the liver of the DL-buthionine-(S,R)-sulfoximine (BSO)-treated rats dosed with m-DCB, both of 2,4- and 3,5-DCPSO2Mes were present at significantly lower concentrations than in non-BSO-treated rats."( Contribution of methylsulfonyl metabolites of m-dichlorobenzene to the heme metabolic enzyme induction by the parent compound in rat liver.
Kato, Y; Kimura, R; Kogure, T; Sato, M, 1988
)
0.27
" Two of the four DMSO trials, and both MSM trials reported significant improvement in pain outcomes in the treatment group compared to comparator treatments, however, methodological issues and concerns over optimal dosage and treatment period, were highlighted."( Systematic review of the nutritional supplements dimethyl sulfoxide (DMSO) and methylsulfonylmethane (MSM) in the treatment of osteoarthritis.
Bashir, N; Brien, S; Lewith, G; Lewith, H; Prescott, P, 2008
)
0.35
" Further studies are now required to identify both the optimum dosage and longer-term safety of MSM and DMSO, and definitive efficacy trials."( Systematic review of the nutritional supplements dimethyl sulfoxide (DMSO) and methylsulfonylmethane (MSM) in the treatment of osteoarthritis.
Bashir, N; Brien, S; Lewith, G; Lewith, H; Prescott, P, 2008
)
0.35
"125 grams 3 times daily for 12 weeks and the other received a placebo in the same dosing frequency."( Efficacy of methylsulfonylmethane supplementation on osteoarthritis of the knee: a randomized controlled study.
Agar, G; Beer, Y; Debbi, EM; Debi, R; Elbaz, A; Fichman, G; Halperin, N; Kardosh, R; Ziv, YB, 2011
)
0.37
" This limitation can probably be addressed by a dosage increase over the first 4 weeks and by extending treatment by 1 or 2 months."( Co-analgesic therapy for arthroscopic supraspinatus tendon repair pain using a dietary supplement containing Boswellia serrata and Curcuma longa: a prospective randomized placebo-controlled study.
Dellabiancia, F; Ingardia, A; Merolla, G; Paladini, P; Porcellini, G, 2015
)
0.42
"Combination therapy, which reduces the dosage intensity of the individual drugs while increasing their efficacy, is not a novel approach for the treatment of cancer."( The combination of methylsulfonylmethane and tamoxifen inhibits the Jak2/STAT5b pathway and synergistically inhibits tumor growth and metastasis in ER-positive breast cancer xenografts.
Chang, SH; Cho, BW; Darvin, P; Hwang, TS; Joung, YH; Kang, DY; Kim, DN; Kim, HS; Kim, SY; Kim, WS; Lee, HK; Park, JH; Park, KD; S P, N; Yang, YM; Yoo, YB, 2015
)
0.42
" The pharmacokinetics of the constituents of these supplements when dosed in combination with methylsulfonylmethane were compared to being administered alone."( Pharmacokinetic assessment of constituents of Boswellia serrata, pine bark extracts, curcumin in combination including methylsulfonylmethane in healthy volunteers.
Adiwidjaja, J; Eagles, SK; Eyles, J; Hunter, DJ; Liu, X; McLachlan, AJ; Wang, X, 2020
)
0.56
" Three days prior to and one day after a race, the daily dosage was doubled."( Optimized Curcumin, Pomegranate Extract, and Methylsulfonylmethane Reduce Acute, Systemic Inflammatory Response to a Half-marathon Race.
Davis, AA; Gary, MA; McFarlin, BK; Michalik, S; Tanner, EA, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
sulfoneAn organosulfur compound having the structure RS(=O)2R (R =/= H).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (3)

PathwayProteinsCompounds
dimethyl sulfone degradation06
superpathway of dimethylsulfone degradation219
dimethyl sulfide degradation II (oxidation)814

Protein Targets (24)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency39.81070.177814.390939.8107AID2147
RAR-related orphan receptor gammaMus musculus (house mouse)Potency4.32770.006038.004119,952.5996AID1159521
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency66.40670.001530.607315,848.9004AID1224841; AID1224848; AID1224849
67.9K proteinVaccinia virusPotency3.23110.00018.4406100.0000AID720579; AID720580
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency19.95260.031610.279239.8107AID884; AID885
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cereblon isoform 4Magnetospirillum gryphiswaldenseIC50 (µMol)373,500.00003.53006.31007.8000AID1277063; AID1277066
Cereblon isoform 4Magnetospirillum gryphiswaldenseKi335,075.00000.64203.94289.6000AID1277067; AID1277070
Choline O-acetyltransferase Rattus norvegicus (Norway rat)Ki144,000.00000.00020.00130.0030AID30246; AID30248
Protein cereblonHomo sapiens (human)IC50 (µMol)181,000.00000.28601.70663.0000AID1277064
Protein cereblonHomo sapiens (human)Ki137,490.00001.49006.580010.0000AID1277068
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (7)

Processvia Protein(s)Taxonomy
protein ubiquitinationProtein cereblonHomo sapiens (human)
positive regulation of Wnt signaling pathwayProtein cereblonHomo sapiens (human)
negative regulation of protein-containing complex assemblyProtein cereblonHomo sapiens (human)
positive regulation of protein-containing complex assemblyProtein cereblonHomo sapiens (human)
negative regulation of monoatomic ion transmembrane transportProtein cereblonHomo sapiens (human)
locomotory exploration behaviorProtein cereblonHomo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProtein cereblonHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (3)

Processvia Protein(s)Taxonomy
protein bindingProtein cereblonHomo sapiens (human)
transmembrane transporter bindingProtein cereblonHomo sapiens (human)
metal ion bindingProtein cereblonHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (7)

Processvia Protein(s)Taxonomy
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
nucleusProtein cereblonHomo sapiens (human)
cytoplasmProtein cereblonHomo sapiens (human)
cytosolProtein cereblonHomo sapiens (human)
membraneProtein cereblonHomo sapiens (human)
perinuclear region of cytoplasmProtein cereblonHomo sapiens (human)
Cul4A-RING E3 ubiquitin ligase complexProtein cereblonHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (16)

Assay IDTitleYearJournalArticle
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1277068Inhibition of MANT-uracil binding to human CRBN (delta 1 to 315) by Cheng-Prusoff equation analysis2016Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2
A FRET-Based Assay for the Identification and Characterization of Cereblon Ligands.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1277065Inhibition of MANT-uracil binding to Caenorhabditis elegans CRBN (delta 1 to 15) by FRET assay2016Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2
A FRET-Based Assay for the Identification and Characterization of Cereblon Ligands.
AID1277063Inhibition of MANT-uracil binding to wild type Magnetospirillum gryphiswaldense cereblon isoform 4 by FRET assay2016Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2
A FRET-Based Assay for the Identification and Characterization of Cereblon Ligands.
AID1277064Inhibition of MANT-uracil binding to human CRBN (delta 1 to 315) by FRET assay2016Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2
A FRET-Based Assay for the Identification and Characterization of Cereblon Ligands.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID30246Compound was evaluated for reversible inhibition of hydrolysis acetylcholine by acetylcholinesterase and represented as KI(com)1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Effects of charge, volume, and surface on binding of inhibitor and substrate moieties to acetylcholinesterase.
AID1277066Inhibition of MANT-uracil binding to Magnetospirillum gryphiswaldense cereblon isoform 4 Y101F mutant by FRET assay2016Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2
A FRET-Based Assay for the Identification and Characterization of Cereblon Ligands.
AID30248Compound was evaluated for reversible inhibition of hydrolysis acetylcholine by acetylcholinesterase and represented as KI(noncompetitive)1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Effects of charge, volume, and surface on binding of inhibitor and substrate moieties to acetylcholinesterase.
AID1277069Inhibition of MANT-uracil binding to Caenorhabditis elegans CRBN (delta 1 to 15) by Cheng-Prusoff equation analysis2016Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2
A FRET-Based Assay for the Identification and Characterization of Cereblon Ligands.
AID1277070Inhibition of MANT-uracil binding to Magnetospirillum gryphiswaldense cereblon isoform 4 Y101F mutant by Cheng-Prusoff equation analysis2016Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2
A FRET-Based Assay for the Identification and Characterization of Cereblon Ligands.
AID1277067Inhibition of MANT-uracil binding to wild type Magnetospirillum gryphiswaldense cereblon isoform 4 by Cheng-Prusoff equation analysis2016Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2
A FRET-Based Assay for the Identification and Characterization of Cereblon Ligands.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (217)

TimeframeStudies, This Drug (%)All Drugs %
pre-199027 (12.44)18.7374
1990's15 (6.91)18.2507
2000's50 (23.04)29.6817
2010's89 (41.01)24.3611
2020's36 (16.59)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 45.68

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index45.68 (24.57)
Research Supply Index5.56 (2.92)
Research Growth Index4.93 (4.65)
Search Engine Demand Index132.25 (26.88)
Search Engine Supply Index3.73 (0.95)

This Compound (45.68)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials33 (14.60%)5.53%
Reviews12 (5.31%)6.00%
Case Studies7 (3.10%)4.05%
Observational0 (0.00%)0.25%
Other174 (76.99%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (6)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Effects of Methylsulfonylmethane on Knee Laxity in Active Young Females [NCT03747198]32 participants (Actual)Interventional2019-02-01Completed
[NCT01188213]0 participants InterventionalCompleted
The Effect of Methylsulfonylmethane (MSM) on Cardiometabolic Health [NCT03716791]43 participants (Actual)Interventional2019-02-19Completed
"Multicenter, Prospective, Double-blind, Placebo-controlled, Randomized Study of the Feasibility of Using the Dietary Supplement ARTNEO®, Capsules for Oral Administration in Patients With Stage II-III Primary Knee Osteoarthritis" [NCT05975879]212 participants (Actual)Interventional2022-05-31Completed
The Effect of Methyl-Sulphonyl-Methane on Osteoarthritis and Joint Cartilage Associated With the Degeneration of the Chondrocyte [NCT01836757]Phase 1100 participants (Anticipated)Interventional2012-09-30Recruiting
The Use of Methylsulfonylmethane (MSM) in the Treatment of Low Back Pain. [NCT02268305]Phase 3100 participants (Actual)Interventional2015-02-28Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]